Acute Lymphoblastic Leukemia T-cell Therapy March 13, 2014Posted by stuffilikenet in Awesome, Brilliant words, Mutants, Science.
A Wright’s stained bone marrow aspirate smear of patient with precursor B-cell acute lymphoblastic leukemia.
Cells from the patients’ own bodies are taken and trained to respond to CD19 protein, then re-introduced into them to their owners. Overall response rate for this treatment was 88%; even better, with disease in progress (when the prognosis usually is pretty damn grim) the response rate was still 78%. Among the best bits of news about this is the study is conducted by Memorial Sloan Kettering on 16 patients. They had done another five in a previous study.
This technique can probably be applied to a number of other cancers and diseases as well; targeted immunotherapy is just in its infancy.
Homework: “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia.” M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D. C. G. Bouhassira, M. E. Arcila, M. Gonen, G. J. Roboz, P. Maslak, D. Douer, M. G. Frattini, S. Giralt, M. Sadelain, R. Brentjens. Science Translational Medicine, 2014; 6 (224): 224ra25 DOI: 10.1126/scitranslmed.3008226